Title:
INHIBITORS OF THROMBIN INDUCED PLATELET AGGREGATION
Document Type and Number:
WIPO Patent Application WO2001045641
Kind Code:
A3
Abstract:
The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering a pharmaceutically effective amount of a compound or composition that inhibits JAK-3 and/or tyrosine phosphorylation of STAT-3 and inhibits thrombin induced platelet aggregation. The condition of platelet aggregation includes hematopoietic and cerebrovascular diseases.
Inventors:
UCKUN FATIH M (US)
Application Number:
PCT/US2000/042345
Publication Date:
September 12, 2002
Filing Date:
November 29, 2000
Export Citation:
Assignee:
PARKER HUGHES INST (US)
UCKUN FATIH M (US)
UCKUN FATIH M (US)
International Classes:
A61K31/00; A61K31/517; A61K45/00; A61P7/02; A61P9/00; A61P43/00; C07D239/94; (IPC1-7): A61K31/517; A61P7/02
Domestic Patent References:
| WO1997032856A1 | 1997-09-12 |
Foreign References:
| US5962458A | 1999-10-05 | |||
| US5436233A | 1995-07-25 | |||
| US3800039A | 1974-03-26 |
Other References:
TIBBLES HEATHER A. ET AL.: "Prevention of fatal thromboembolism in mice by selectively targeting Jak 3 kinase in platelets with 4-(4'hydroxyphenyl)-amino-6,7-dimethoxyquinazoline", BLOOD, vol. 96, no. 11part1, 16 November 2000 (2000-11-16), pages 273a, XP002174855
TRIEU, VUONG N. ET AL: "Treatment of atherosclerosis in apolipoprotein E-deficient mice with 4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), a potent inhibitor of triglyceride synthesis", J. CARDIOVASC. PHARMACOL. (2000), 35(2), 179-188, XP001013470
KALMES A ET AL: "Heparin blockade of thrombin-induced smooth muscle cell migration involve inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor.", CIRCULATION RESEARCH, (2000 JUL 21) 87 (2) 92-8., XP001013472
TRIEU, VUONG N. ET AL: "A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis", BIOCHEM. BIOPHYS. RES. COMMUN. (2000), 267(1), 22-25, XP001018912
CHEN, CHUN-LIN ET AL: "Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice", PHARM. RES. (1999), 16(1), 117-122, XP000937666
TRIEU, VUONG N. ET AL: "Treatment of atherosclerosis in apolipoprotein E-deficient mice with 4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), a potent inhibitor of triglyceride synthesis", J. CARDIOVASC. PHARMACOL. (2000), 35(2), 179-188, XP001013470
KALMES A ET AL: "Heparin blockade of thrombin-induced smooth muscle cell migration involve inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor.", CIRCULATION RESEARCH, (2000 JUL 21) 87 (2) 92-8., XP001013472
TRIEU, VUONG N. ET AL: "A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis", BIOCHEM. BIOPHYS. RES. COMMUN. (2000), 267(1), 22-25, XP001018912
CHEN, CHUN-LIN ET AL: "Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice", PHARM. RES. (1999), 16(1), 117-122, XP000937666
Download PDF: